Skip to main content

Body Composition Assessment

Body composition assessment measures fat, lean tissue, muscle size, bone mineral and body water. It can identify muscle depletion that weight or BMI misses. In reconstructive practice, its main role is to complement nutrition, strength and functional assessment when the result can inform care.[1][2]

Low muscle mass on an image is not, by itself, a clinical diagnosis of sarcopenia. EWGSOP2 identifies probable sarcopenia through low strength, confirms it with low muscle quantity or quality, and uses physical performance to grade severity. The AWGS 2025 framework requires concurrent low strength and low muscle mass, with physical performance treated as an outcome rather than a severity category.[3][4]

Why Body Composition Matters Beyond BMI​

BMI does not separate fat from lean mass or describe fat distribution. In a meta-analysis of 25 studies (31,968 patients), commonly used BMI cutoffs for obesity had a pooled sensitivity of 0.50 (95% CI 0.43–0.57) and specificity of 0.90 (0.86–0.94) for high body adiposity.[18] Normal or high BMI also does not exclude muscle depletion. In a single-center CT series of 117 patients with pancreatic cancer, low SMI was found in 79.7% of those with normal BMI and in 50% of overweight patients.[19] It shows why a patient who looks well nourished by weight can still have low muscle mass, a finding that is reported as an imaging result and confirmed with strength testing.

Choosing a Method​

MethodMain informationUseful applicationInterpretation limits
AnthropometryWeight trajectory, BMI, waist or calf circumferenceInitial assessment; trained bedside assessment when equipment is unavailableBMI does not distinguish muscle from fat; edema and adiposity complicate circumference measurements
DXAFat mass, appendicular lean soft tissue, bone mineralWidely used muscle-mass estimate in sarcopenia assessmentLean tissue includes water and nonmuscle tissue; scanner differences and fluid shifts affect results. Pregnant patients should not undergo DXA; screen patients of childbearing potential before scanning.[1] ASPEN 2020 made a strong recommendation, based on low-quality evidence, for DXA fat-mass assessment in adults with a specific disease or clinical outcome; it found DXA lean-mass validity in those populations unknown.[7]
Air displacement plethysmography (BodPod)Body volume and density, converted to fat mass in a two-compartment modelRadiation-free whole-body fat estimate in stable outpatientsNeeds dedicated equipment; assumes fixed fat-free mass density and hydration, which may not hold in illness, edema or older age
BIAImpedance-derived body-water and lean-mass estimates; phase anglePortable assessment using an appropriate validated equationDoes not directly measure muscle; hydration, device and reference population matter. For patients with pacemakers or other implanted cardiac devices, check BIA device labeling and local restrictions before use.[1]
CTMuscle cross-sectional area and attenuation; visceral/subcutaneous fatSecondary analysis of a recent clinically indicated scanRadiation precludes routine new scanning solely for this purpose; contrast and acquisition protocol affect measurements
MRIMuscle volume and fat infiltrationSelected research or specialist assessmentCost, access and protocol variation
UltrasoundRegional muscle thickness, area and echogenicityBedside assessment by trained operatorsOperator and site dependence; cutoffs and clinical validation remain less standardized

These methods are not interchangeable. The 2026 ACR criteria rate DXA as usually appropriate for suspected sarcopenia in adults aged 60 or older and in adults with cancer, cachexia or malnutrition, frailty, or multiple comorbidities and support opportunistic analysis of available CT scans; a recent suitable CT may avoid an additional DXA examination. ACR does not support ordering a new CT or MRI solely for routine initial sarcopenia assessment.[2]

Compartment Models and Measurement Conditions​

A two-compartment model divides the body into fat and fat-free mass. Three-compartment models vary by method (DXA separates fat mass, lean soft tissue and bone mineral), while four-compartment models estimate fat, water, mineral and protein.[1][5] More detailed models reduce dependence on fixed assumptions but do not eliminate biological or technical error. A simplified four-compartment model that combines DXA and BIA takes about 10 minutes of patient time. In 23 healthy adults it matched the criterion four-compartment estimate of percent fat with R² 0.96.[5]

For serial assessment, document the device, equation, anatomical site, positioning, hydration and acquisition conditions. Changes between scanners or after substantial fluid administration can resemble tissue change. Standardized conditions matter. In 32 athletic men, non-fasted afternoon testing changed fat-free-mass estimates substantially for BIA spectroscopy and for the three- and four-compartment models, and only slightly for DXA. DXA and air displacement remained acceptable when acute food and fluid intake stayed below 500 g.[6] A single small change is not interpreted as confirmed nutritional recovery.[1]

Bioelectrical Impedance and Phase Angle​

BIA applies a small alternating current and measures impedance; phase-sensitive devices also measure phase shift, allowing resistance and reactance to be derived.[1] Predictive equations estimate body compartments. Fat-free mass is a good conductor because of its water and electrolyte content, and fat is a poor one. Single-frequency systems (usually 50 kHz) estimate total-body impedance. Multifrequency systems and bioimpedance spectroscopy separate intracellular from extracellular water. Segmental systems measure arms, legs and trunk separately. These systems give different outputs and cannot automatically share cutoffs.[7][8][9]

Phase angle, expressed in degrees, is derived from arctangent(reactance/resistance). It is associated with cellular and hydration characteristics, but is not a direct assay of membrane integrity or nutritional adequacy. The 2020 ASPEN validity guideline found insufficient evidence to recommend BIA or ultrasound for body-composition assessment across clinical populations; subsequent consensus use of validated methods in specified populations should not be confused with universal device accuracy.[7][10]

A systematic review of critically ill patients found an association between low phase angle and mortality (pooled RR 1.82, 95% CI 1.46–2.26).[11] Certainty was low to very low and more than 40% of included studies had high risk of bias.[11] Proposed sarcopenia cutoffs vary by study, population and measurement protocol.[11][12]

Phase angle has been associated with outcomes in other populations, and each association is observational:

  • In a systematic review of 13 studies (7,668 participants), 7 of 8 studies comparing phase angle by sarcopenia status found lower phase angle in sarcopenia; proposed identification cutoffs ranged from 3.55° to 5.05°.[12]
  • In a prospective cohort of 100 outpatients with cirrhosis, phase angle ≤4.6° (n = 31) versus >4.6° (n = 69) was associated with higher estimated 2-year probabilities of hospitalization (35% vs 11%), falls (41% vs 11%) and death (26% vs 3%).[20]
  • In 4,452 community-dwelling adults aged 65 or older, low phase angle (4.95° or less in men, 4.35° or less in women) was associated with incident disability over 24 months (HR 1.95, 95% CI 1.37–2.78).[21]
  • In a retrospective cohort of 858 patients undergoing elective cardiovascular surgery, higher preoperative phase angle was independently associated with lower all-cause mortality after discharge during a mean 909-day follow-up (HR 0.91 per 0.1° increment; 95% CI 0.87–0.95).[22]

No universal phase-angle threshold exists for postponing or permitting reconstructive surgery. If phase angle is used locally, interpret it alongside the broader assessment and document device and measurement conditions for serial comparisons.

Opportunistic CT Muscle Assessment​

An axial L3 skeletal muscle area can be indexed to height squared to obtain SMI (cm²/m²). Muscle attenuation in Hounsfield units provides different information about tissue composition. Record the muscle group, level, segmentation method, reference population and contrast phase.[1][13]

Reconstructive patients often already have a suitable scan: pre-cystectomy or pre-RPLND staging CT, pelvic imaging before exenteration, trauma CT in pelvic fracture urethral injury, or surveillance CT urography. Automated segmentation at the workstation is moving this analysis from research into clinical use.[23]

The often-quoted 52.4 cm²/m² in men and 38.5 cm²/m² in women are historical oncology research cutoffs and not universal EWGSOP2 diagnostic thresholds or validated operative-clearance limits for every GU procedure. Other cancer studies use BMI-dependent or population-specific thresholds. Interpret low SMI as an imaging finding and assess strength before diagnosing clinical sarcopenia.[13][3]

In a meta-analysis of 38 studies including 7,843 patients with nonhematologic solid tumors, low CT-derived skeletal muscle index was associated with poorer overall survival (HR 1.44, 95% CI 1.32–1.56) and cancer-specific survival (HR 1.93, 95% CI 1.38–2.70).[14]

When L3 is unavailable, alternate CT slices from C3 to L1 have been studied in adults with cancer, but none has been validated against whole-body skeletal muscle mass.[15] A systematic review found substantial methodological variability and insufficient evidence for a definitive interchangeable alternative; do not apply an L3 cutoff directly to T4 or T12.[15]

Sarcopenia, Malnutrition and Obesity​

These conditions overlap but answer different clinical questions:

  • Sarcopenia. Strength is assessed together with muscle quantity, and the selected consensus framework is applied consistently; see Handgrip Strength.[3][4]
  • GLIM malnutrition. Diagnosis needs at least one phenotypic criterion and one etiologic criterion. Reduced muscle mass is one possible phenotype; weight loss or low BMI may provide another. The 2025 update states that handgrip testing should not be used as a surrogate for muscle mass. Calf or arm anthropometry and subjective muscle assessment by trained clinicians are acceptable when advanced devices are unavailable. CRP is recommended for confirmation when inflammatory status is uncertain, and clinical judgment may suffice otherwise.[16]
  • Sarcopenic obesity. It combines impaired muscle function and reduced muscle mass with excess adiposity.[4]

CT or MRI can quantify visceral adipose tissue, while DXA and BIA provide different estimates. In a UK Biobank comparison, DXA-estimated visceral fat volume had a stronger association with MRI-derived visceral fat volume (R² 0.94) than BIA-estimated trunk fat mass (R² 0.49); R² denotes coefficients of determination.[17]

Application Before and After Reconstruction​

Use a suitable existing staging or surveillance scan when muscle assessment is clinically relevant. Combine it with intake and weight history, examination, strength, mobility and frailty assessment. An abnormal result should prompt assessment of reversible contributors and appropriate dietetic or rehabilitation input. It does not create an automatic waiting period or a requirement to normalize SMI before surgery. Muscle assessment is most often considered before major bowel-based diversion, complex pelvic reconstruction, gender-affirming surgery and graft-based urethroplasty. Interpret the result alongside a separate frailty assessment. In a meta-analysis of 21 observational studies of 4,997 patients undergoing radical cystectomy, study-defined sarcopenia was associated with 90-day complications (OR 1.77, 95% CI 1.23–2.55) and all-cause mortality (HR 1.45, 95% CI 1.32–1.61).[24] The sources cited here do not support deferring surgery on body-composition data alone.

After bowel-based urinary reconstruction, evaluate persistent acidosis and other bone-health risks. Bone-density DXA and whole-body composition DXA are distinct examinations. Select bone-density testing according to fracture risk and clinical indications. See Renal Function & Metabolic Surveillance and Vitamin D.

See Also​

References​

1. Prado CM, Gonzalez MC, Norman K, et al. "Methodological Standards for Body Composition Assessment — an Expert-Endorsed Guide for Research and Clinical Applications: Bioimpedance, DXA, CT, and Ultrasound Methods." The American Journal of Clinical Nutrition. 2026;123(5):101283. doi:10.1016/j.ajcnut.2026.101283

2. Expert Panel on Musculoskeletal Imaging, Boutin RD, Lenchik L, et al. "ACR Appropriateness Criteria® Diagnosis and Monitoring of Sarcopenia." Journal of the American College of Radiology. 2026. doi:10.1016/j.jacr.2026.02.007

3. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." Age and Ageing. 2019;48:16–31. doi:10.1093/ageing/afy169. See also the published correction.

4. Chen LK, Hsiao FY, Akishita M, et al. "A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update." Nature Aging. 2025;5:2164–2175. doi:10.1038/s43587-025-01004-y.

5. Ng BK, Liu YE, Wang W, et al. "Validation of Rapid 4-Component Body Composition Assessment With the Use of Dual-Energy X-Ray Absorptiometry and Bioelectrical Impedance Analysis." The American Journal of Clinical Nutrition. 2018;108(4):708–715. doi:10.1093/ajcn/nqy158

6. Kerr A, Slater GJ, Byrne N. "Impact of Food and Fluid Intake on Technical and Biological Measurement Error in Body Composition Assessment Methods in Athletes." The British Journal of Nutrition. 2017;117(4):591–601. doi:10.1017/S0007114517000551

7. Sheean P, Gonzalez MC, Prado CM, et al. "ASPEN Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations." JPEN. Journal of Parenteral and Enteral Nutrition. 2020;44(1):12–43. doi:10.1002/jpen.1669

8. Sergi G, De Rui M, Stubbs B, Veronese N, Manzato E. "Measurement of Lean Body Mass Using Bioelectrical Impedance Analysis: A Consideration of the Pros and Cons." Aging Clinical and Experimental Research. 2017;29(4):591–597. doi:10.1007/s40520-016-0622-6

9. Silva AM, Campa F, Stagi S, et al. "The Bioelectrical Impedance Analysis (BIA) International Database: Aims, Scope, and Call for Data." European Journal of Clinical Nutrition. 2023;77(12):1143–1150. doi:10.1038/s41430-023-01310-x

10. Norman K, Herpich C, Müller-Werdan U. "Role of Phase Angle in Older Adults With Focus on the Geriatric Syndromes Sarcopenia and Frailty." Reviews in Endocrine & Metabolic Disorders. 2023;24(3):429–437. doi:10.1007/s11154-022-09772-3

11. Lima J, Eckert I, Gonzalez MC, Silva FM. "Prognostic Value of Phase Angle and Bioelectrical Impedance Vector in Critically Ill Patients: A Systematic Review and Meta-Analysis." Clinical Nutrition. 2022;41(12):2801–2816. doi:10.1016/j.clnu.2022.10.010

12. Di Vincenzo O, Marra M, Di Gregorio A, Pasanisi F, Scalfi L. "Bioelectrical Impedance Analysis (BIA) — Derived Phase Angle in Sarcopenia: A Systematic Review." Clinical Nutrition. 2021;40(5):3052–3061. doi:10.1016/j.clnu.2020.10.048

13. McGovern J, Dolan RD, Horgan PG, Laird BJ, McMillan DC. "Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review." Journal of Cachexia, Sarcopenia and Muscle. 2021;12(6):1408–1417. doi:10.1002/jcsm.12831

14. Shachar SS, Williams GR, Muss HB, Nishijima TF. "Prognostic Value of Sarcopenia in Adults With Solid Tumours: A Meta-Analysis and Systematic Review." European Journal of Cancer. 2016;57:58–67. doi:10.1016/j.ejca.2015.12.030

15. Vangelov B, Bauer J, Kotevski D, Smee RI. "The Use of Alternate Vertebral Levels to L3 in CT Scans for Skeletal Muscle Mass Evaluation and Sarcopenia Assessment in Patients With Cancer: A Systematic Review." The British Journal of Nutrition. 2022;127(5):722–735. doi:10.1017/S0007114521001446

16. Jensen GL, Cederholm T, Correia MITD, et al. "GLIM consensus approach to diagnosis of malnutrition: A 5-year update." JPEN. 2025;49:414–427. doi:10.1002/jpen.2756.

17. Chan B, Yu Y, Huang F, Vardhanabhuti V. "Towards Visceral Fat Estimation at Population Scale: Correlation of Visceral Adipose Tissue Assessment Using Three-Dimensional Cross-Sectional Imaging With BIA, DXA, and Single-Slice CT." Frontiers in Endocrinology. 2023;14:1211696. doi:10.3389/fendo.2023.1211696

18. Okorodudu DO, Jumean MF, Montori VM, et al. "Diagnostic Performance of Body Mass Index to Identify Obesity as Defined by Body Adiposity: A Systematic Review and Meta-Analysis." International Journal of Obesity. 2010;34(5):791–799. doi:10.1038/ijo.2010.5

19. Khristenko E, Sinitsyn V, Rieden T, et al. "CT-Based Screening of Sarcopenia and Its Role in Cachexia Syndrome in Pancreatic Cancer." PLoS One. 2024;19(1):e0291185. doi:10.1371/journal.pone.0291185

20. Román E, Poca M, Amorós-Figueras G, et al. "Phase Angle by Electrical Bioimpedance Is a Predictive Factor of Hospitalisation, Falls and Mortality in Patients With Cirrhosis." Scientific Reports. 2021;11(1):20415. doi:10.1038/s41598-021-99199-8

21. Uemura K, Doi T, Tsutsumimoto K, et al. "Predictivity of Bioimpedance Phase Angle for Incident Disability in Older Adults." Journal of Cachexia, Sarcopenia and Muscle. 2020;11(1):46–54. doi:10.1002/jcsm.12492

22. Shibata K, Kameshima M, Adachi T, et al. "Association Between Preoperative Phase Angle and All-Cause Mortality After Cardiovascular Surgery: A Retrospective Cohort Study." Journal of Cachexia, Sarcopenia and Muscle. 2024;15(4):1558–1567. doi:10.1002/jcsm.13514

23. Bates DDB, Pickhardt PJ. "CT-Derived Body Composition Assessment as a Prognostic Tool in Oncologic Patients: From Opportunistic Research to Artificial Intelligence-Based Clinical Implementation." AJR American Journal of Roentgenology. 2022;219(4):671–680. doi:10.2214/AJR.22.27749

24. Qin F, Wu J. "Impact of sarcopenia on outcomes of bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis." Scott Med J. 2024;69(2):26-36. doi:10.1177/00369330241234690